Auto parts maker KHAT has bagged over $63 million in a Series D1 round, while Huaqiu Electronics has raised almost $44 million. In a separate development, HighLight Capital has invested in German radiopharmaceutical firm ITM.
Auto parts maker KHAT bags over $63m
KH Automotive Technologies, also known as KHAT, which produces air suspension systems for passenger vehicles, has secured 450 million yuan ($63.6 million) in a Series D1 round.
The round was jointly backed by a 10-billion-yuan fund managed by GAC Capital, the investment arm of state-owned automaker Guangzhou Automobile Group; and BOC Asset Management, the investment arm of Bank of China (BOC). The proceeds will be used for product R&D and expanding the production capacity, per the release.
Founded in June 2007, the Huzhou-based firm had previously raised 510 million yuan ($72.4 million) in a Series B round led by China Venture Capital, Source Code Capital, and Shenzhen Capital Group, among others, in November 2022.
Huaqiu Electronics snaps almost $44m
Huaqiu Electronics, which provides PCB board manufacturing through its online platform, has snapped 310 million ($43.8 million) in a Series C++ round led by local investment firm QF Capital and Pengrui Industry Investment.
The funding round, which saw the participation of Yunmu Capital and several other existing investors, will help the company expand its production capacity, according to a press release on Thursday.
Founded in 2011, the Shenzhen-based firm previously bagged 300 million yuan ($46 million) in a Series C+ round led by GL Ventures, with participation from Joy Capital and Shunwei Capital in August 2021.
HighLight Capital backs German radiopharmaceutical firm ITM
Shanghai-based private investment firm HighLight Capital (HLC) has participated in a secondary transaction of Munich-based radiopharmaceutical biotech firm ITM Isotope Technologies Munich SE (ITM).
Founded in 2004, ITM engages in the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
The strategic investment comes four months after ITM secured an investment of 188 million euros ($205.4 million) in a round led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne, in June.